WO2004029226A3 - Methods for altering cell fate to generate t-cells specific for an antigen of interest - Google Patents

Methods for altering cell fate to generate t-cells specific for an antigen of interest Download PDF

Info

Publication number
WO2004029226A3
WO2004029226A3 PCT/US2003/008120 US0308120W WO2004029226A3 WO 2004029226 A3 WO2004029226 A3 WO 2004029226A3 US 0308120 W US0308120 W US 0308120W WO 2004029226 A3 WO2004029226 A3 WO 2004029226A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
interest
generate
methods
cells specific
Prior art date
Application number
PCT/US2003/008120
Other languages
French (fr)
Other versions
WO2004029226A2 (en
Inventor
Philippe Collas
James M Robl
Bjorn S Skalhegg
Original Assignee
Nucleotech Llc
Philippe Collas
James M Robl
Bjorn S Skalhegg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucleotech Llc, Philippe Collas, James M Robl, Bjorn S Skalhegg filed Critical Nucleotech Llc
Priority to AU2003295309A priority Critical patent/AU2003295309A1/en
Priority to US10/426,595 priority patent/US7491534B2/en
Publication of WO2004029226A2 publication Critical patent/WO2004029226A2/en
Publication of WO2004029226A3 publication Critical patent/WO2004029226A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4645—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Abstract

The invention provides methods for altering the expression profile of a cell to convert the cell from one cell type to a desired cell type (e.g, T-cells). These reprogrammed cells may be used in a variety of medical applications for treating a mammal in need of a particular cell type.
PCT/US2003/008120 2000-12-22 2003-03-14 Methods for altering cell fate to generate t-cells specific for an antigen of interest WO2004029226A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003295309A AU2003295309A1 (en) 2002-04-30 2003-03-14 Methods for altering cell fate to generate t-cells specific for an antigen of interest
US10/426,595 US7491534B2 (en) 2000-12-22 2003-04-30 Methods for altering cell fate to generate T-cells specific for an antigen of interest

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37665302P 2002-04-30 2002-04-30
US60/376,653 2002-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/015,824 Continuation-In-Part US20020142397A1 (en) 2000-12-22 2001-12-10 Methods for altering cell fate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/426,595 Continuation US7491534B2 (en) 2000-12-22 2003-04-30 Methods for altering cell fate to generate T-cells specific for an antigen of interest

Publications (2)

Publication Number Publication Date
WO2004029226A2 WO2004029226A2 (en) 2004-04-08
WO2004029226A3 true WO2004029226A3 (en) 2006-04-06

Family

ID=32043119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/008120 WO2004029226A2 (en) 2000-12-22 2003-03-14 Methods for altering cell fate to generate t-cells specific for an antigen of interest

Country Status (2)

Country Link
AU (1) AU2003295309A1 (en)
WO (1) WO2004029226A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108103027B (en) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） Method for reprogramming blood cells with high efficiency and simultaneously realizing gene editing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945577A (en) * 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6215041B1 (en) * 1997-01-10 2001-04-10 University Of Mmassachusetts Cloning using donor nuclei from a non-quiesecent somatic cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945577A (en) * 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US6215041B1 (en) * 1997-01-10 2001-04-10 University Of Mmassachusetts Cloning using donor nuclei from a non-quiesecent somatic cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COLLAS P. ET AL: "Reprogrammed gene expression in a somatic cell-free extract.", TRANSGENIC RESEARCH., vol. 11, no. 1, February 2002 (2002-02-01), pages 75, XP001204972 *
KIKYO N. ET AL: "Active Remodeling of Somatic Nucleic in Egg Cytoplasm by the Nucleosomal ATPase ISWI.", SCIENCE., vol. 289, September 2000 (2000-09-01), pages 2360 - 2362, XP002217930 *
LANDSVERK H.B. ET AL: "Reprogrammed gene expression in a somatic cell-free extract.", EMBO REPORTS., vol. 3, no. 4, April 2002 (2002-04-01), pages 384 - 389, XP002317367 *
RENARD J.P. ET AL: "Nuclear Transfer Technologies Between Successes and Doubts.", THERIOGENOLOGY., vol. 57, no. 1, January 2002 (2002-01-01), pages 203 - 222, XP001066227 *

Also Published As

Publication number Publication date
AU2003295309A8 (en) 2004-04-19
AU2003295309A1 (en) 2004-04-19
WO2004029226A2 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
WO2002057415A3 (en) Method for altering cell fate
WO2007024898A3 (en) Displays with integrated photovoltaic cells
AU2003216058A8 (en) Mammalian neural stem cells, compositions and uses thereof
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
WO2006101814A3 (en) Polymer photovoltaic cell
HK1122583A1 (en) Dimercaptan terminated polythioether polymers and methods for making and using the same
WO2008036374A3 (en) Allogeneic stem cell transplants in non-conditioned recipients
AU2003294783A1 (en) Semiconductor structure, and methods for fabricating same
WO2007079183A3 (en) Placental stem cell populations
WO2006119305A3 (en) Ultra and very-high efficiency solar cells
WO2007067782A3 (en) Compositions and methods for inducing the activation of immature monocytic dendritic cells
WO2007143204A3 (en) Compositions and methods for modifying cell surface glycans
MY163032A (en) Human anti-il-23 antibodies, compositions, methods and uses
NO20065355L (en) Materials which contain a hollow glucan particle or a cell wall component encapsulating a terpene component, as well as methods for using the same
TW200733453A (en) Method of using an electrochemical cell
WO2007028079A3 (en) Methods of stimulating expansion of hematopoietic stem cells
EP1693405A4 (en) Proton conducting membrane and process for producing the same
DK1553832T3 (en) Cell separation preparations and methods
AU2019268061A1 (en) Placental stem cell populations
AU2003255035A1 (en) Method for testing precursor of secondary cell, its testing instrument, and method for manufacturing secondary cell using the method
ITMI20042255A1 (en) EEPROM CELL AND EEPROM DEVICE WITH HIGH INTEGRATION AND LOW SOURCE RESISTANCE AND PROCESS OF MANUFACTURING THE SAME TIMES
WO2007011665A3 (en) Diffraction foils
WO2006039396A3 (en) Non-embedded tissue microarray technology for protein and nucleic acid analyses
WO2004112175A3 (en) Oxidation facilitator
WO2008057068A3 (en) Micro-aluminum galvanic cells and methods for constructing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10426595

Country of ref document: US

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP